NOT FOR DISTRIBUTION
Header cover image

Theralase Technologies

Market Cap

CA$42.9m

Last Updated

2021/05/10 22:31 UTC

Data Sources

Company Financials +

Executive Summary

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Theralase Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TLT is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: TLT's weekly volatility (12%) has been stable over the past year.


Market Performance


7 Day Return

-2.3%

TLT

-5.0%

CA Medical Equipment

1.2%

CA Market


1 Year Return

-10.6%

TLT

24.4%

CA Medical Equipment

35.5%

CA Market

Return vs Industry: TLT underperformed the Canadian Medical Equipment industry which returned 32.5% over the past year.

Return vs Market: TLT underperformed the Canadian Market which returned 36.9% over the past year.


Shareholder returns

TLTIndustryMarket
7 Day-2.3%-5.0%1.2%
30 Day-20.8%-12.0%1.7%
90 Day-8.7%-27.0%6.8%
1 Year-10.6%-10.6%24.4%24.4%39.9%35.5%
3 Year-2.3%-2.3%77.8%77.8%29.4%17.1%
5 Year-44.7%-44.7%81.8%81.8%59.0%35.2%

Long-Term Price Volatility Vs. Market

How volatile is Theralase Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Theralase Technologies undervalued compared to its fair value and its price relative to the market?

4.68x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TLT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TLT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TLT is unprofitable, so we can't compare its PE Ratio to the North American Medical Equipment industry average.

PE vs Market: TLT is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLT is good value based on its PB Ratio (4.7x) compared to the CA Medical Equipment industry average (5.5x).


Future Growth

How is Theralase Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

37.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLT's revenue (71.3% per year) is forecast to grow faster than the Canadian market (6.7% per year).

High Growth Revenue: TLT's revenue (71.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLT is forecast to be unprofitable in 3 years.


Past Performance

How has Theralase Technologies performed over the past 5 years?

-5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLT is currently unprofitable.

Growing Profit Margin: TLT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLT is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare TLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (26.7%).


Return on Equity

High ROE: TLT has a negative Return on Equity (-61.1%), as it is currently unprofitable.


Financial Health

How is Theralase Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: TLT's short term assets (CA$8.9M) exceed its short term liabilities (CA$821.4K).

Long Term Liabilities: TLT's short term assets (CA$8.9M) exceed its long term liabilities (CA$35.7K).


Debt to Equity History and Analysis

Debt Level: TLT is debt free.

Reducing Debt: TLT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TLT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 2.8% each year.


Dividend

What is Theralase Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.4yrs

Average management tenure


CEO

Shawn Shirazi

1.58yrs

Tenure

CA$347,148

Compensation

Dr. Shawn Shirazi, Ph.D., M.Sc., B.Sc., is Chief Executive Officer at Theralase Technologies Inc. since October 31, 2019 and served as its Chief Executive Officer of Drug since February 25, 2019 until Octo...


CEO Compensation Analysis

Compensation vs Market: Shawn's total compensation ($USD287.25K) is above average for companies of similar size in the Canadian market ($USD156.55K).

Compensation vs Earnings: Insufficient data to compare Shawn's compensation with company performance.


Leadership Team

Experienced Management: TLT's management team is seasoned and experienced (11.4 years average tenure).


Board Members

Experienced Board: TLT's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TLT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Theralase Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theralase Technologies Inc.
  • Ticker: TLT
  • Exchange: TSXV
  • Founded: 1995
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$42.898m
  • Shares outstanding: 204.28m
  • Website: https://www.theralase.com

Number of Employees


Location

  • Theralase Technologies Inc.
  • 41 Hollinger Road
  • Toronto
  • Ontario
  • M4B 3G4
  • Canada

Listings


Biography

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Can...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 22:31
End of Day Share Price2021/05/10 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.